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Abstract
Objectives Medication errors that lead to adverse drug reactions are a key cause of unintentional patient harm and subse-
quent economic burden. To prevent this, measurement of renal function could be considered. The aim of this study was to 
determine the budget impact of obtaining and evaluating renal function in community pharmacies in the Netherlands to 
prevent antibiotic-related hospitalizations.
Methods A decision model was built to simulate the process of antibiotic prescriptions in community pharmacies with and 
without the use of a point-of-care test (PoCT) in patients aged 65 years and older. By using a PoCT, the number of patients 
with renal function values available increases, leading to the possibility of dose adjustment when necessary. In turn, this 
might avoid hospitalizations. For this study, real-life patient data were used from 351 community pharmacies. Direct costs 
of renal function screening, antibiotic treatments, and medical care due to antibiotic-related hospitalization were included.
Results The budget impact analysis showed annual cost-savings of €86 per patient through the availability of renal function 
values in Dutch community pharmacies. Savings were mostly due to avoided hospitalizations.
Conclusion Obtaining and evaluating renal function in community pharmacies by point of care tests is expected to be cost-
saving in the Netherlands.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4025 8-018-0426-2) contains 
supplementary material, which is available to authorized users.
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Key Points for Decision‑Makers 
The use of a renal point-of-care test could reduce the 
number of adverse event-related hospitalizations from 
antibiotics.
Using a renal point-of-care test in community pharma-
cies might be a cost-saving alternative to the standard of 
care.
1 Introduction
Medication errors and adverse drug events are impor-
tant causes of unintentional patient harm and may lead to 
hospitalizations [1]. Additionally, the incidence of renal 
impairment is increasing, potentially caused by the aging 
population and the worldwide increasing incidence of 
hypertension and diabetes mellitus [2]. A decreased renal 
function is one of the risk factors for drug-related hospital 
admissions. In fact, this causes 10% of all medication-related 
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hospitalizations. Adjustment of the dosage, dose interval, or 
drug substitution could prevent these hospitalizations [3].
In case of an impaired kidney function, medication moni-
toring is often crucial, thus the availability of an up-to-date 
renal function value, as well as a sufficient medication 
monitoring system, is important. More awareness by gen-
eral practitioners (GPs) and specialists might help to reduce 
adverse drug events, as might interventions from community 
pharmacists such as renal function-based dose adjustments 
or drug substitutions [4, 5].
In routine clinical care, renal function is estimated (esti-
mated glomerular filtration rate, eGFR) from a serum cre-
atinine value, using a formula that also includes age, sex, 
and race as variables [6]. Unfortunately, eGFR values are 
often absent in community pharmacies, mostly due to the 
absence of a patient’s permission to exchange laboratory 
values between healthcare professionals [7]. Additionally, 
an overload of medication-monitoring signals leads to alert 
fatigue. To increase the relevance of medication-monitoring 
signals in case of impaired renal function, medical-phar-
maceutical decision rules (MFBs) are developed, which are 
linked to the patient’s age [4]. Furthermore, it is important 
to immediately start with antibiotics to prevent exacerbations 
and the spreading of bacteria in case of an infection. When 
a recent eGFR value is unavailable, renal function measure-
ment should be initiated by the prescriber, blood should be 
drawn at a diagnostic center, and serum creatinine analyzed 
in a lab, which may take up to several days [3, 4].
In addition to the burden for the patient, the inappropri-
ate prescribing of antibiotics in case of unknown impaired 
renal function can laed to high medical costs. The total direct 
medical costs for preventable adverse events were €161 mil-
lion in 2004 in the Netherlands [8]. The proportion of anti-
biotic-related adverse events due to unknown renal function 
is still unknown.
The use of a point-of-care test (PoCT) might increase the 
availability of renal functions in community pharmacies by 
motivating prescribers to share these values with pharma-
cists, as well as by using the PoCT itself. A PoCT is a device 
that provides medical diagnostic testing near the point-of-
care, which is the time and place of patient care. In 2015 a 
PoCT for renal function measurement was introduced in the 
Netherlands in 336 community pharmacies. The importance 
and relevance of better medication monitoring in community 
pharmacies in patients with renal impairment is described in 
a previously published study by Heringa et al. [4, 9].
The aim of this study was to carry out a budget impact 
analysis of obtaining and evaluating eGFR values in patients 
presenting themselves with antibiotic prescriptions in com-
munity pharmacies in the Netherlands, using a renal PoCT.
2  Methods
2.1  Model Design
A decision model was built in Microsoft Excel 2016 to 
assess the budget impact on healthcare costs by increas-
ing the number of available renal functions by using the 
StatSensor® Point of Care Creatinine and eGFR Analyzer 
[10, 11]. This PoCT is a handheld, miniature biosensor for 
wholeblood creatinine testing and provides an assessment 
of renal function by finger stick capillary blood sampling, 
which can be executed in the community pharmacy [12]. 
The standard of care (SoC) was simulated by incorporating 
medication monitoring with impaired renal function in com-
munity pharmacies. Currently, prescribers should initiate the 
gathering of renal functions in patients who are at risk of 
renal impairment. Community pharmacies can obtain these 
renal function values from the prescriber or from the LSP, 
which is a secure network for sharing medical information 
electronically [13]. When the necessary information is una-
vailable, obtaining a renal function might take up to several 
days, while antibiotic treatment has to start immediately. The 
pharmacist will then deliver the antibiotic without evalua-
tion of renal function values, which is a risk that might lead 
to adverse events and hospitalizations. In this model, the 
SoC was compared to the introduction of MFBs and the 
PoCT (Appendix 1, Figs. 2 and 3). An MFB generates an 
alert when dose adjustment is advised, based on a registered 
impaired renal function or when renal function information 
is lacking for people over 70 years old, with a prescription 
for a drug for which this information is considered impor-
tant [4]. The goal of introducing the MFBs and PoCT is to 
increase the availability of renal function values in com-
munity pharmacies, with the possibility of obtaining such 
values when urgently needed. ISPOR budget impact analysis 
principles of good practice were used to ensure good meth-
odology. The model was validated using the Assessment of 
the Validation Status of Health-Economic decision models 
(AdViSHE) tool [14]. Renal impairment is categorized from 
normal to end-stage renal disease based on eGFR following 
advice of the European Medicines Agency (EMA, Table 1) 
[15].
Table 1  Categorization of renal impairment by eGFR value





< 10 End-stage renal disease
57Budget Impact Analysis of a Renal Point-of-Care Test
The antibiotics considered were amoxicillin/clavulanic 
acid, ciprofloxacin, clarithromycin, cotrimoxazole, nitro-
furantoin, norfloxacin, and trimethoprim, because these 
require an intervention in case of decreased renal function 
[4]. Dose adaptations were based on The Royal Dutch Phar-
macists Association guidelines, which are also available 
from the National Health Care Institute [16, 17]. To evaluate 
the budget impact, the model was populated with 1,000,000 
patients.
2.2  Study Population and Time Horizon
The anonymous patient data included 117,190 patients 
from 351 Service Apotheek pharmacies in the Netherlands. 
Patients who received drugs other than antibiotics and 
patients without a clear prescription handling pathway were 
excluded from the analysis. This analysis focuses on antibi-
otics since a direct start of therapy is indicated, as opposed 
to the other drugs, where a few days delay might be accept-
able. Ultimately, 88,514 patients were included (Fig. 1). 
The dataset contained information regarding patients’ year 
of birth, gender, prescribed medication, (handling of) MFB 
signals, the use of the PoCT, and eGFR values.
This analysis was performed from the healthcare payers’ 
perspective. In line with the budgeting process of the Dutch 
health system, as well as the ISPOR guidelines for budget 
impact analyses, a time horizon of 1 year was chosen. As 
the PoCT was introduced in 2015, we modelled from the 1 
January until the 31 December 2016, to avoid potential start-
up-phase data gathering problems in the Service Apotheek 
project. Among other things, their project aimed to investi-
gate the frequency and management of drug therapy alerts 
about drug use in patients with (potential) renal impairment 
as well as the contribution of PoCT in community pharma-
cies to the availability renal function information [4].
2.3  PoCT
The patient dataset reflecting the included study population 
was the main source for estimating transition probabilities 
in the decision model (Appendix 2, Table 7). Patient char-
acteristics are displayed in Table 2 [9]. When patients had 
more than one prescription of interest in the studied year 
(and therefore were in the dataset more than once), we only 
used their information if there was a > 13-month interval 
between visits. If this was less than 13 months, we used the 
first renal function value.
Fig. 1  Inclusion and exclusion of patients from the Service Apotheek dataset for the budget impact analysis
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From the confidential validation report, Table 3 illustrates 
the test characteristics of the StatSensor Creatinine PoCT at 
an eGFR < 30, since intervention is only required for these 
patients according to The Royal Dutch Pharmacists Asso-
ciation guidelines [16]. The dataset showed 4.71% of all 
patients have an eGFR < 30. The percentage of renal func-
tions measured by the PoCT with eGFR < 30 was 0.76%. 
Hospitalization caused by adverse events of antibiotic treat-
ment was assumed to be 0.1% from the number of severe 
adverse events [16].
2.4  Costs
Costs are shown in Table 4 with respective references [18, 
19]. We assumed one PoCT per pharmacy was sufficient for 
at least the timeframe of 1 year, at a price of €250. Every 
measurement requires a new strip for blood sampling. Cur-
rently the use of a PoCT is not reimbursed, so either the 
pharmacist or the patient must pay for the use of the PoCT. 
The SoC costs resulted from antibiotic treatment costs and 
medical care from antibiotic-related hospitalizations due to 
an unknown impaired renal function. The specific costs of 
adverse events due to inappropriate dose adjustment follow-
ing renal impairment are unknown. Therefore these costs 
were derived from the Dutch Cost Manual, which describes 
the average costs per hospital day, the average length of stay, 
and the costs of an emergency room (ER) and intensive care 
unit (ICU) visit [19].
The costs of the new situation resulted from costs of renal 
function measurement using the PoCT, treatment with anti-
biotics, and medication-related hospitalization due to an 
impaired renal function. The impact of the different assump-
tions in the model was assessed in a univariate sensitivity 
analyses for the initial (base-case) analysis. All costs were 
inflated to the year 2016 for the purpose of consistency and 
using the appropriate deflators [20]. The costs for the PoCT 
apparatus and strips were based on information from Ser-
vice Apotheek and Menarini Diagnostics, the Netherlands 
[21, 22].
2.5  Scenario Analyses
Scenario analyses were conducted to evaluate the budget 
impact at different levels of increased availability of renal 
function values. Since the baseline value was 46.07% renal 
function unavailability in all subjects, the percentage of val-
ues provided by the prescriber/laboratory and from the PoCT 
was increased by 5, 10, and 20%.
Table 2  Patient characteristics 
of the Service Apotheek 
dataset from 351 community 
pharmacies
Characteristics






Table 3  Sensitivity and 









Table 4  Costs included in the 
budget impact analysis, 2016 
price levels
dd daily dosage, PoCT point-of-care test
a Costs for all antibiotic prescriptions include a consultation with the prescriber (assumed to be the general 
practitioner, €33 [19])





€36.90 [18] Change dose to 875/125 mg 2 dd €35.23 [18]
Ciprofloxacin 500 mg 2 dd €35.20 [18] Change dose to 500 mg 1 dd €34.89 [18]
Clarithromycin 250 mg 2 dd €36.92 [18] 50% of dose €34.37 [18]
Cotrimoxazole 960 mg 2 dd €34.71 [18] 50% of dose €33.52 [18]
Nitrofurantoin 50 mg 4 dd €33.73 [18] Change to trimethoprim €35.60 [18]
Norfloxacin 400 mg 2 dd €38.21 [18] Change dose to 400 mg 1 dd €35.60 [18]
Trimethoprim 300 mg 1 dd €33.52 [18] 3 days normal dose, then 50% of dose €33.52 [18]
Hospitalization €5347.52 [19]
PoCT per strip  [3] €5.40
Statsensor Creatinine €250
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3  Results
3.1  Budget Impact Analysis
Our analysis shows that an increased availability of renal 
function information in community pharmacies through 
the use of a PoCT is potentially cost-saving. Annual hospi-
talization costs due to renal function-related adverse events 
were €230.108.680. The total annual costs per patient were 
€264.20 and €178.12 for the SoC and the PoCT, respec-
tively, leading to cost savings of €86.08.
In 2016 the Netherlands counted 1994 community phar-
macies, meaning the database we used included information 
of 17.6% of all community pharmacies [23]. Considering the 
database consisted of 88,514 patients of interest, this leads 
to an annual number of 502.760 patients with antibiotic pre-
scriptions, of which 231,622 would have an unknown eGFR. 
These data imply that availability of information on renal 
function in all relevant cases could add up to cost savings of 
€19,938,021 per year in the Netherlands.
3.2  Scenario Analyses
Scenario analyses show that savings might add up to more 
than €207 per patient if the introduction of a creatinine 
PoCT would lead to availability of almost all necessary renal 
functions (Table 5).
In the univariate sensitivity analysis, the parameters were 
varied over a range of 75–125% of the deterministic values 
from Table 4. We excluded the percentage of adverse events 
(5.7%) from the univariate sensitivity analysis, since this 
only has a small effect on the outcome. The univariate sen-
sitivity analysis shows that hospitalization costs, PoCT costs, 
and cost of dose per consultation with the prescriber have 
the most influence on the outcomes of the analysis (Table 6).
4  Discussion
To our knowledge, this is the first economic analysis study-
ing the obtainment and evaluation of renal function values 
in community pharmacies, using a PoCT. The results of this 
analysis show that obtaining eGFR values by using the PoCT 
in Dutch pharmacies might be a cost-saving alternative to 
the current practice.
The use of real patients’ data in this study increases the 
reliability of the analysis, as the data contained complete 
information on the process of antibiotic prescriptions in 
the included pharmacies, with all corresponding registered 
eGFR values. Data from 88,514 patients was included in the 
study, which is a large and relevant study population.
If this study took quality of life of patients into account, 
we postulate that patients would generally feel better due to 
averted hospitalizations, as this would outweigh the burden 
of the PoCT. Additionally, the PoCT provides a quick and 
accurate result. This is why pharmacists might be likely to 
implement the use of a renal PoCT to improve pharmaceuti-
cal care [24].
As with all economic analyses, this study has some limi-
tations. Firstly, several assumptions had to be made in order 
to complete the model. The most important ones were used 
in the SoC modelling (renal function provided by the GP/
laboratory and the amount of patients in this population with 
an eGFR < 30). For future research, assumptions could be 
validated with patient-level data to increase the robustness 
of the model.
No specific number of antibiotic-related adverse events 
due to impaired renal function was found, so general drug-
related adverse events data was used [25]. Since this value 
includes all drugs that might cause side effects due to a lack 
of monitoring in patients with impaired renal function, the 
percentage of antibiotic-related adverse events is likely to 
be different.
Table 5  Scenario analyses: 
cost savings by increasing the 
availability of eGFR values 









Renal function provided by GP/laboratory − €101.31 − €116.54 − €147.01
Renal function provided by PoCT − €101.04 − €116.01 − €145.94
Renal function provided by GP/laboratory and PoCT − €116.28 − €146.48 − €206.87
Table 6  Univariate sensitivity analysis







PoCT apparatus costs (€187.50; 
€312.50)
− € 86.51 − € 85.65
PoCT strip costs (€4.05; €6.75) − € 86.16 − € 86.00
Hospitalization costs (€4010.64; 
€6684.40)
− € 64.03 − € 108.12
Costs of dose consultation with pre-
scriber (€26.99; €44.99)
− € 86.14 − € 86.01
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When a patient has a PoCT result that indicates renal 
failure, the outcome should be confirmed by a laboratory 
test initiated by the general practitioner. We did not take 
these cost into account because this is unrelated to antibi-
otic delivery and treatment. For the same reason we did not 
include costs that come from this result in the future, such 
as treatment. Had we included confirmation costs, the out-
come would potentially be less favorable, but could still be 
cost-saving.
To conclude, our findings show that the availability of 
information on renal function in community pharmacies may 
be a cost-saving alternative to the SoC. More research is 
needed, to evaluate the impact of increased information on 
renal function for other drug categories, where the impact 
might be bigger than for antibiotics.Additionally more 
research should be conducted to evaluate the cost of the 
inappropriate prescription of medication.
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Appendix 1: Decision model
See Figs. 2 and 3.
Fig. 2  Decision model ‘Standard of Care’. AE adverse events, GFR glomerular filtration rate, GP general practitioner, RF renal function
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Fig. 3  Decision model ‘PoCT’. AE adverse events, GFR glomerular filtration rate, GP general practitioner, PoCT point of care test, RF renal 
function
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